{
  "abstract": "We read with great interest the national UK service evaluation by Lumsden et al, describing the increasing use of transdermal clonidine patches (TCPs) in children and young people with severe motor disorders.1 The study persuasively underscores both the clinical complexity of this population and the growing reliance on alpha-2 agonists despite the limited evidence base.",
  "authors": [
    {
      "affiliations": [
        "University of Trieste, Department of Medical, Surgical and Health Sciences, Trieste, Italy",
        "Institute for Maternal and Child Health IRCCS \"Burlo Garofolo”, Trieste, Italy"
      ],
      "name": "Francesca Peri"
    },
    {
      "affiliations": [
        "Institute for Maternal and Child Health IRCCS \"Burlo Garofolo”, Trieste, Italy"
      ],
      "name": "Francesca Burlo"
    },
    {
      "affiliations": [
        "Institute for Maternal and Child Health IRCCS \"Burlo Garofolo”, Trieste, Italy"
      ],
      "name": "Lucia De Zen"
    }
  ],
  "title": "Alpha-2 agonists for severe childhood hypertonia: is it time to look beyond clonidine?",
  "uid": "96e1ba89-75b3-55ee-98cf-e7bbf7a1cede"
}